Aristotelis Bamias1, Axel Hegele2, Jacques Medioni3, Daniel Castellano4, Laura Doni5, Rodolfo Passalacqua6, Flora Zagouri7, Kimon Tzannis8, Syed Hussain9, Anders Ullen10. 1. Department of Clinical Therapeutics, University of Athens, National and Kapodistrian University of Athens Alexandra Hospital, 80 Vas. Sofias Avenue, 11528 Athens, Greece. Electronic address: abamias@med.uoa.gr. 2. Department of Urology and Pediatric Urology, University Medical Center, Baldingerstreet, 35033 Marburg, Germany. Electronic address: hegele@med.uni-marburg.de. 3. Centre d'Essais Précoces en Cancérologie, Hopital European Georges Pompidou, Paris-Descartes University, 20, rue Leblanc, 75015 Paris, France. Electronic address: Jacques.medioni@aphp.fr. 4. Hospital Universitario 12 de Octubre, Av Cordoba s/n, 28041 Madrid, Spain. Electronic address: cdanicas@hotmail.com. 5. Aienda Ospedaliera Careggi U.O., Medical Oncology, 3, Largo Brambilla, 50134 Firenze, Italy. Electronic address: doni.laura@gmail.com. 6. Oncology Department, ASST Istituti Ospitalieri, Viale Concordia 1, 26100 Cremona, Italy. Electronic address: r.passalacqua@asst-cremona.it. 7. Department of Clinical Therapeutics, University of Athens, National and Kapodistrian University of Athens Alexandra Hospital, 80 Vas. Sofias Avenue, 11528 Athens, Greece. Electronic address: florazagouri@yahoo.co.uk. 8. Department of Clinical Therapeutics, University of Athens, National and Kapodistrian University of Athens Alexandra Hospital, 80 Vas. Sofias Avenue, 11528 Athens, Greece. Electronic address: kimon.tzannis@gmail.com. 9. Academic Unit of Clinical Oncology, Department of Oncology and Metabolism, The Medical School, Beech Hill Road, Sheffield S10 2RX, UK. Electronic address: syed.hussain@sheffield.ac.uk. 10. Karolinska University Hospital, Eugeniavägen 3, PO Bäckencancer, Theme Cancer, Solna 17176, Sweden. Electronic address: anders.ullen@sll.se.
Abstract
BACKGROUND: Vinflunine (VFL) is approved in Europe as second-line treatment of metastatic urothelial cancer after failure of platinum-containing therapy. We performed a systematic review and meta-analysis of real-world data (RWD) to assess utilization, efficacy and safety of VFL. METHODS: We performed a MEDLINE search for the period of 1/1/2000-31/8/2017. Full-length articles providing post-marketing RWD on VFL in patients failing previous chemotherapy were eligible. Interventional clinical trials were excluded. RESULTS: Ten studies with 797 patients were identified. According to pooled REs analysis, overall response rate was 19%, most frequent, all-grade toxicities were fatigue (41%), constipation (39%), nausea/vomiting (25%), and most prevalent Grade 3-4 toxicities were neutropenia (13%), anaemia (9%), fatigue (8%). Median OS was comparable to results reported in recent randomized studies. CONCLUSION: Our findings confirm the efficacy and safety of VFL in an unselected population and support the use of VFL in the changing treatment paradigm of relapsed mUC.
BACKGROUND:Vinflunine (VFL) is approved in Europe as second-line treatment of metastatic urothelial cancer after failure of platinum-containing therapy. We performed a systematic review and meta-analysis of real-world data (RWD) to assess utilization, efficacy and safety of VFL. METHODS: We performed a MEDLINE search for the period of 1/1/2000-31/8/2017. Full-length articles providing post-marketing RWD on VFL in patients failing previous chemotherapy were eligible. Interventional clinical trials were excluded. RESULTS: Ten studies with 797 patients were identified. According to pooled REs analysis, overall response rate was 19%, most frequent, all-grade toxicities were fatigue (41%), constipation (39%), nausea/vomiting (25%), and most prevalent Grade 3-4 toxicities were neutropenia (13%), anaemia (9%), fatigue (8%). Median OS was comparable to results reported in recent randomized studies. CONCLUSION: Our findings confirm the efficacy and safety of VFL in an unselected population and support the use of VFL in the changing treatment paradigm of relapsed mUC.
Authors: Felix Riedel; Mara Münker; Florian Roghmann; Johannes Breyer; Marco J Schnabel; Maximilian Burger; Danijel Sikic; Thomas Büttner; Manuel Ritter; Kiriaki Hiller; Felix Wezel; Christian Bolenz; Friedemann Zengerling Journal: Cancers (Basel) Date: 2022-06-09 Impact factor: 6.575